SynthesisAsian Pacific journal of cancer prevention : APJCP2025
Insights on Survival and Recurrence After Surgery in Malignant Meningiomas: A Systematic Review and Meta-Analysis.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant meningiomas (WHO Grade III) are rare, aggressive tumors with poor prognosis and high recurrence rates. Gross total resection (GTR) is the preferred treatment; however, recurrence remains a challenge, especially after subtotal resection (STR). The role of adjuvant radiotherapy (RT) and chemotherapy in improving patient outcomes remains controversial. This systematic review and meta-analysis assessed the impact of surgical extent, adjuvant therapies, and prognostic factors on survival and recurrence of malignant meningiomas.
methodsA systematic review and meta-analysis were conducted using the PubMed, Cochrane Library, and Scopus databases. Eligible studies included retrospective and prospective cohorts, case-control studies, and clinical trials reporting the surgical extent (GTR vs. STR), adjuvant therapy, survival, and recurrence. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk of Bias Tool. Meta-analysis was performed using random- and fixed-effects models and heterogeneity was assessed using the I² statistic.
resultsSixteen studies (2,208 patients) met the inclusion criteria. The 5-year overall survival (OS) ranged from 40% to 90%, with GTR significantly improving survival (HR = 0.54, 95% CI: 0.50-0.58, p < 0.00001) [1]. Recurrence rates were lower in GTR cases (50-90% in STR). Adjuvant RT improved progression-free survival (HR = 0.36, 95% CI: 0.18-0.70) in STR patients, but its benefit post-GTR was unclear. Chemotherapy had no significant effect on patient survival [2]. Key prognostic factors included tumor location, patient age, Ki-67 index, and histology [3, 4].
conclusionGTR is the strongest predictor of long-term survival, whereas STR requires adjuvant RT for disease control. The role of chemotherapy remains uncertain, necessitating further research into targeted therapies. Standardized treatment protocols and long-term surveillance are essential to improve patient outcomes [5].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.